PARP Inhibitors for the Treatment of BRCA1/ 2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis
Background: The PARP inhibitors (PARPis) olaparib and talazoparib are currently approved for the treatment of deleterious germline BRCA1/2-mutated (gBRCA+) metastatic breast cancer (MBC). These approvals were based on improvements in progression-free survival (PFS) observed in two randomized control...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Serier: | Hematology/Oncology and Stem Cell Therapy |
| Fag: | |
| Online adgang: | https://journals.lww.com/10.56875/2589-0646.1033 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|